Urogen Pharma Ltd
(URGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -30,213 | -109,783 | -80,914 | -55,083 | -28,392 |
| Depreciation Amortization | -137 | 426 | 595 | 618 | 265 |
| Accounts receivable | 211 | -987 | 2,288 | 122 | 2,218 |
| Other Working Capital | -1,238 | -6,306 | -7,090 | -9,012 | -3,630 |
| Other Operating Activity | 5,570 | 29,091 | 19,314 | 15,160 | 5,543 |
| Operating Cash Flow | $-25,807 | $-87,559 | $-65,807 | $-48,195 | $-23,996 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 6,293 | 1,314 | -21,807 | 13,533 | 13,621 |
| PPE Investments | -23 | -254 | -241 | -88 | -25 |
| Investing Cash Flow | $6,270 | $1,060 | $-22,048 | $13,445 | $13,596 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 95,783 | 70,793 | 70,793 | 70,831 |
| Common Stock Issued | 671 | 1,511 | 1,133 | 16 | N/A |
| Other Financing Activity | 0 | -160 | -160 | -144 | -89 |
| Financing Cash Flow | $671 | $97,134 | $71,766 | $70,665 | $70,742 |
| Beginning Cash Position | 56,220 | 45,586 | 45,587 | 45,586 | 45,587 |
| End Cash Position | 37,354 | 56,221 | 29,498 | 81,501 | 105,929 |
| Net Cash Flow | $-18,866 | $10,635 | $-16,089 | $35,915 | $60,342 |
| Free Cash Flow | |||||
| Operating Cash Flow | -25,807 | -87,559 | -65,807 | -48,195 | -23,996 |
| Capital Expenditure | -23 | -254 | -241 | -88 | -25 |
| Free Cash Flow | -25,830 | -87,813 | -66,048 | -48,283 | -24,021 |